For the full landscape of peptides for diabetes treatment including all six FDA-approved GLP-1 agonists, tirzepatide, pramlintide, and the investigational triple agonist retatrutide see our dedicated diabetes peptides guide
Thymosin Alpha-1, or T1, is a peptide thats becoming quite popular in the field of functional and regenerative medicine as one of the most clinically-studied immune-modulating peptides available
You need fewer units per dose but each unit carries more peptide, leaving less room for error
Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026
Anti-inflammatory activity reduces markers (interleukin 6, tumor necrosis factor alpha), which aligns with improved recovery conditions